Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
PHVS is expected to report earnings to rise 5.60% to -63 cents per share on April 14
Q4'25
Est.
$-0.63
Q3'25
Beat
by $0.08
Q2'25
Missed
by $0.06
Q1'25
Missed
by $0.12
Q4'24
Beat
by $0.08
The last earnings report on November 12 showed earnings per share of -60 cents, beating the estimate of -67 cents. With 703.63K shares outstanding, the current market capitalization sits at 1.60B.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. PHVS showed earnings on November 12, 2025. You can read more about the earnings report here.